• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Advisory Committees

  • Print
  • Share
  • E-mail

Waivers for Conflicts of Interest for the May 2, 2013 Meeting of the Oncologic Drugs Advisory Committee

 
Persons with disabilities having problems accessing the PDF file(s) below may call (301) 796-3634 for assistance
 
Disclaimer
The Food and Drug Administration Amendments Act of 2007 (FDAAA), enacted on September 27, 2007, added a new provision regarding financial conflicts of interest, § 712 of the Federal Food, Drug, and Cosmetic Act (FD&C Act), effective October 1, 2007. Accordingly, for advisory committee meetings after October 1, 2007, FDA is granting waivers under 18 U.S.C. § 208 and § 712 of the FD&C Act, where applicable, when the relevant waiver standards in these statutes are met.
Waivers under 21 U.S.C. § 355(n)(4) were issued before October 1, 2007.  This provision was repealed, effective October 1, 2007, by the FDA.

 
Wen-Jen Hwu, M.D., Ph.D.
 
18 U.S.C. 208(a) Waiver for the May 2, 2013 Meeting of the Oncologic Drugs Advisory Committee (PDF-25KB)
 
Disclosure Document for the May 2, 2013 Meeting of the Oncologic Drugs Advisory Committee (PDF-12KB)
 
Takami Sato, M.D., Ph.D.
 
18 U.S.C. 208(a) Waiver for the May 2, 2013 Meeting of the Oncologic Drugs Advisory Committee (PDF-3555KB)
 
Disclosure Document for the May 2, 2013 Meeting of the Oncologic Drugs Advisory Committee (PDF-13KB)